Abstract: This invention relates to novel oxoazepine derivatives of Formula (I),R.sup.1 R.sup.2 NCOCH.sub.2 N(R.sup.3)COR.sup.4 (I)to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.
Type:
Grant
Filed:
April 14, 1997
Date of Patent:
August 1, 2000
Assignee:
Glaxo Wellcome Inc.
Inventors:
Milana Dezube, Gavin Charles Hirst, Ronald George Sherrill, Elizabeth Ellen Sugg, Jerzy Ryszard Szewczyk, Timothy Mark Willson
Abstract: The present invention is directed to spiro-substituted azacycles of the Formula 1: ##STR1## (wherein R.sub.1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
Type:
Grant
Filed:
December 12, 1997
Date of Patent:
October 5, 1999
Assignee:
Merck & Co., Inc.
Inventors:
Sander G. Mills, Malcolm Maccoss, Martin S. Springer
Abstract: The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Type:
Grant
Filed:
December 31, 1996
Date of Patent:
March 23, 1999
Assignees:
Dr. Reddy's Research Foundation, Reddy-Cheminor, Inc.
© 2024 Justia
